21世纪桥本脑病的再审视
该研究评估了24例符合桥本脑病(HE)治疗前标准的患者,发现仅31.6%对激素完全应答,且甲状腺过氧化物酶抗体(TPOAb)在各类对照组中频率相似(8.1% vs 8.2%,p=0.84),提示现有标准不能预测激素反应且TPOAb疾病特异性差。
要点
- 现有HE治疗前标准不能预测激素应答,仅31.6%完全应答。
- TPOAb在可能的自身免疫性脑炎及其他对照组中频率相似,特异性差。
- NH2-α-烯醇化酶抗体对HE诊断无帮助。
核心结论
- 当前HE治疗前标准不能预测激素反应性,TPOAb疾病特异性差,NH2-α-烯醇化酶抗体无诊断价值,提示需重新定义HE并系统排除抗体介导的脑炎。
研究设计与样本
- 评估24例符合HE治疗前标准的患者(14例女性,中位年龄48岁,范围8-79岁)的临床表现和激素反应性。
- 在74例无神经元抗体的可能自身免疫性脑炎患者和205例不同神经免疫疾病、精神病或NORSE患者中检测TPOAb(>200 IU/mL)。
- 在24例疑似HE患者和13例对照中检测NH2-α-烯醇化酶抗体。
主要发现
- 24例疑似HE患者中,精神症状7例(29%)、脑病7例(29%)、NORSE样6例(25%)、边缘性脑炎4例(17%)。
- 19例患者中仅6例(31.6%)对激素完全应答。
- 74例可能AE患者中TPOAb频率为6/74(8.1%),205例对照中为17/205(8.2%),p=0.84。
- NH2-α-烯醇化酶抗体在24例疑似HE中检出1例,13例对照中检出1例。
关键数值与推荐
- HE治疗前标准包括:亚急性起病的认知障碍、精神症状或癫痫发作;甲状腺功能正常或轻度甲减;血清TPOAb>200 IU/mL;血清/CSF无神经元抗体;无其他病因。
- TPOAb>200 IU/mL在可能AE患者中频率8.1%,对照组8.2%,p=0.84。
临床怎么用
- 临床诊断HE时应系统排除抗体介导的脑炎,不应仅凭TPOAb阳性诊断。
- 激素反应性不能作为HE的支持依据,仅少数患者完全应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report the presenting syndromes and to determine whether pretreatment criteria of Hashimoto encephalopathy (HE) predict response to steroids. METHODS: We assessed symptoms and steroid responsiveness in 24 patients with pretreatment criteria of HE, including (1) subacute onset of cognitive impairment, psychiatric symptoms, or seizures; (2) euthyroid status or mild hypothyroidism; (3) serum thyroid peroxidase antibodies (TPOAb) >200 IU/mL; (4) absent neuronal antibodies in serum/CSF; and (5) no other etiologies. Additional studies included determination of TPOAb (>200 IU/mL) in 74 patients with criteria of possible autoimmune encephalitis (AE) without neuronal antibodies and 205 patients with different neuroimmunologic diseases, psychosis, or new-onset refractory status epilepticus (NORSE). Serum antibodies to the amino (ΝΗ2)-terminal of α-enolase (NH2-α-enolaseAb) were examined in the indicated 24 patients and 13 controls. RESULTS: The 24 patients (14 women) with suspected HE had a median age of 48 years (range 8-79 years). Four syndromes were identified: psychiatric (7, 29%), encephalopathy (7, 29%), NORSE-like (6, 25%), and limbic encephalitis (4, 17%). Only 6 of 19 (31.6%) patients completely responded to steroids. The frequency of TPOAb in the 74 patients with possible AE (6 of 74, 8.1%) was similar to that of the 205 controls (17 of 205, 8.2%; p = 0.84). NH2-α-enolaseAb were identified in 1 of 24 suspected HE cases and 1 of 13 controls. CONCLUSION: Current pretreatment criteria of HE do not predict steroid responsiveness. The detection of TPOAb across all control groups reveals their poor disease-specificity. NH2-α-enolaseAb did not help in the diagnosis of HE. These findings imply a redefinition of HE that requires a systematic exclusion of antibody-mediated encephalitis.
引用
- Mattozzi S, Sabater L, Escudero D, et al. Hashimoto encephalopathy in the 21st century. Neurology. 2019. PMID: 31882532. doi:10.1212/WNL.0000000000008785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。